Physician profile
Caleb Davis
NPI 1528416427
$11,596.35
in general payments reported to CMS, 2019-2025
11 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.20 · 2020: $722 · 2021: $2,368 · 2022: $591 · 2023: $3,423 · 2024: $4,258 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,079 · Consulting Fee: $2,250 · Food and Beverage: $1,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,078.81 |
| Consulting Fee | $2,250.00 |
| Food and Beverage | $1,524.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vilex LLC | $4,176.77 | 2023-2024 | |
| Arthrex, INC. | $2,643.76 | 2021-2024 | Distal Extremities Implants Foot & Ankle Metal Compression Screws |
| Paragon 28, INC. | $1,328.92 | 2023 | Portfolio |
| Cdc Medical LLC | $1,253.97 | 2020-2024 | |
| Treace Medical Concepts, INC. | $1,150.36 | 2022-2025 | |
| Stryker Corporation | $778.73 | 2020-2025 | Augment Injectable |
| Zimmer Biomet Holdings, INC. | $80.65 | 2019-2021 | |
| Heron Therapeutics, INC. | $72.47 | 2022 | |
| Biocomposites INC | $48.04 | 2024 | |
| Organogenesis INC. | $33.35 | 2021 | |
| Smith+Nephew, INC. | $29.33 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.